OPDIVO Bristol-Myers Squibb Australia Pty Ltd
Product name
OPDIVO
Accepted date
Jul-2024
Active ingredients
nivolumab
Proposed indication
For the treatment of patients with unresectable or metastatic colorectal cancer.
Application type
C (new indication)
Publication date
Jul-2024